| Message: | https://www.sarmshgpharm.com/sarms-list/lgd-3033/sarm-lgd3033-reviews%ef%bc%8cbenefits%ef%bc%8cdosage%ef%bc%8ccycle-and-side-effect/
LGD3033 is a derivative of LGD4033, which is a refined and structurally different SARM.
Ligand Pharmaceuticals Incorporated (LGND), the developer of LGD4033, announced preclinical data on SARM LGD3033 on September 16, 2007, showing the effects of LGD3033 on bone mineral density and strength.
In fact, LGD4033 and LGD3033 are not that far apart.
Dr. Martin D. Mcglasson, vice president of Discovery Research at Ligand, described the use of LGD3033 to increase bone mineral density in the femur, spine, and more, aiding in the deposition of new bone, among other functions.
In terms of dose, it is difficult to say whether LGD3033 is more effective than LGD4033, although many believe that LGD3033 is more effective.
Unlike LGD4033, LGD3033 is generally consider to be a dry compound. Therefore, when used in the cutting stage, it does not blur the muscle.
The reason dry compounds are ideal during the cutting phase is that once bodybuilder has removed excess fat, compounds that tend to retain subcutaneous moisture hide the muscle profile of bodybuilder, which is the opposite of what bodybuilder is trying to achieve during cutting.
|
my account
